Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
Publication Date: July 27, 2020
Key Recommendations
Key Recommendations
- Screen all patients prior to starting systemic anticancer therapy with three tests: hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc, total Ig or IgG), and antibody to hepatitis B surface antigen (anti-HBs).
- Patients with positive HBsAg or positive anti-HBc may require additional monitoring and/or antiviral treatment.
Diagnosis
All patients with cancer anticipating systemic anticancer therapy should be tested for HBV by three tests prior to, or at the beginning of, systemic anticancer therapy:
- hepatitis B surface antigen (HBsAg)
- hepatitis B core antibody (anti-HBc) total immunoglobulin (Ig) or IgG
- antibody to hepatitis B surface antigen (anti-HBs)
Note: Anticancer therapy should not be delayed for the results of these screening tests. Findings of chronic HBV (HBsAg-positive) or past HBV (HBsAg-negative and anti-HBc-positive with either negative or positive anti-HBs) infection require reactivation risk assessment.
7341
Treatment
...reatment...
...patients receiving any systemic antican...
Hormonal therapy without systemic...
...th past HBV receiving anticancer therapies...
...ents with past HBV undergoing anticancer ther...
...nitions of HBV Reactivation and OutcomesHaving t...
...e 2. Interpretation of HBV Test Resul...
Figure 1. Hepatitis B Virus Screening...